Emily Kleczko

Emily Kleczko, PhD, is an experienced scientific leader in cell line engineering, currently serving as a Scientific Lead at Eli Lilly and Company since August 2024 and as a Senior Scientist at Loxo Oncology at Lilly since November 2022. Previously, Emily held positions at the University of Colorado Anschutz Medical Campus as an Instructor and Postdoctoral Research Fellow, focusing on the progression of lung adenocarcinoma and autosomal dominant polycystic kidney disease. Emily's academic qualifications include a PhD in Cancer Biology from the University of Colorado Anschutz Medical Campus and a BS in Biology from The George Washington University. Emily's extensive research background encompasses various advanced techniques, along with experience in teaching and mentoring in an academic setting.